A Phase 3 interventional study of Placebo and Brexpiprazole in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 107 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-09.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 2nd largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 9th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,986 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one has the largest enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2013, is one of 21 in phase 3, and was the 18th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
The total duration of the study was 32 weeks and the study consisted of Periods A, B, and A+. Patients entered the study in Period A and were treated open-label with one of six commercially available antidepressant treatments (ADTs) for 8 weeks. Patients who met the blinded response criteria at the Week 6 Visit, were deemed early responders and were withdrawn from the study. At Week 8, patients with inadequate response to placebo + ADT, as per the randomisation criteria, entered Period B and were randomised to received double-blind brexpiprazole + ADT or placebo + ADT for 24 weeks. Non-randomised patients continued in Period A+ and received placebo + ADT until the end of the study. The primary objective was to compare the efficacy and safety of brexpiprazole with placebo. This comparison occurred Period B; therefore, the focus is Period B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Drug: Placebo · Drug: ADT
Brexpiprazole adjunct to open-label treatment with a commercially available ADT
Drug: Brexpiprazole · Drug: ADT
Once daily, tablets, orally
1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Full Remission During the Randomised Treatment Period
Full remission is defined as a Montomery and Åsberg Depression Rating Scale (MADRS) total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomized treatment. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.
Time frame: From randomisation to end of Period B (24 weeks)
Full Functional Remission During the Randomised Treatment Period
Full functional remission is defined as a Sheehan Disability Scale (SDS) total score \<=6 and all SDS domain scores \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Time frame: From randomisation to end of Period B (24 weeks)
Full Global Score Remission During the Randomised Treatment Period
Full global score remission is defined as a Clinical Global Impression - Severity of Illness (CGI-S) score \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis, on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Time frame: From randomisation to end of Period B (24 weeks)
Total Time in Remission During the Randomised Treatment Period
The total time the patient spends in remission during randomised treatment. Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score. Time in remission is defined as the sum of days over all periods between Period B visits where remission was obtained. The period between two visits is counted as in remission if the patient was in remission when the period started.
Time frame: From randomisation to end of Period B (24 weeks)
Time to Full Remission During the Randomised Treatment Period
The time from randomisation until full remission has been obtained. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment. The time to full remission was calculated using Kaplan-Meier Methods.
Time frame: From randomisation to end of Period B (24 weeks)
Full Remission Sustained During the Randomised Treatment Period
Full remission sustained is defined as having obtained full remission and remain in remission until completion of the study. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment.
Time frame: From randomisation to end of Period B (24 weeks)
Change From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.
Time frame: From randomisation to week 6
Change From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.
Time frame: From randomisation to end of Period B (24 weeks)
Response at Week 6 During the Randomised Treatment Period
Response is defined as a \>=50% decrease from randomisation in MADRS total score.
Time frame: From randomisation to week 6
Response at Week 24 During the Randomised Treatment Period
Response is defined as a \>=50% decrease from randomisation in MADRS total score.
Time frame: From randomisation to end of Period B (24 weeks)
Remission at Week 6 During the Randomised Treatment Period
Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.
Time frame: From randomisation to week 6
Remission at Week 24 in the Randomised Treatment Period
Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.
Time frame: From randomisation to end of Period B (24 weeks)
Change From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period
The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Time frame: From randomisation to week 6
Change From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period
The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Time frame: From randomisation to end of Period B (24 weeks)
Change From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period
The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Time frame: From randomisation to week 6
Change From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period
The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Time frame: From randomisation to end of Period B (24 weeks)
Change From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period
The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.
Time frame: From randomisation to week 6
Change From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period
The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.
Time frame: From randomisation to end of Period B (24 weeks)
1986 patients were enrolled; 1982 received open-label ADT plus double-blind placebo in the 8-week Period A. In the 24-week Period B, 886 patients were randomised and 885 were treated with open-label ADT plus double-blind brexpiprazole or placebo. Non-randomised patients continued in Period A+ and received open-label ADT plus double-blind placebo.
| Milestone | Period A Placebo and ADT (8 Weeks) | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) | Period A+ Placebo and ADT (Non-randomised Patients) |
|---|---|---|---|---|
| Started | 1986 | 0 | 0 | 0 |
| Completed | 1661 | 0 | 0 | 0 |
| Not completed | 325 | 0 | 0 | 0 |
| Withdrew: Adverse event | 39 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 21 | 0 | 0 | 0 |
| Withdrew: Early response | 148 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 70 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 16 | 0 | 0 | 0 |
| Withdrew: Non-compliance with imp | 6 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 | 0 |
| Withdrew: Withdrawal before treatment | 4 | 0 | 0 | 0 |
| Withdrew: Administrative or other reasons | 17 | 0 | 0 | 0 |
| Milestone | Period A Placebo and ADT (8 Weeks) | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) | Period A+ Placebo and ADT (Non-randomised Patients) |
|---|---|---|---|---|
| Started | 0 | 442 | 444 | 770 |
| Completed | 0 | 380 | 349 | 653 |
| Not completed | 0 | 62 | 95 | 117 |
| Withdrew: Adverse event | 0 | 13 | 27 | 16 |
| Withdrew: Lack of efficacy | 0 | 9 | 11 | 6 |
| Withdrew: Withdrawal by subject | 0 | 28 | 35 | 47 |
| Withdrew: Protocol violation | 0 | 1 | 4 | 6 |
| Withdrew: Non-compliance with imp | 0 | 2 | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 5 | 11 |
| Withdrew: Withdrawal before treatment | 0 | 1 | 0 | 0 |
| Withdrew: Administrative or other reasons | 0 | 6 | 10 | 28 |
Full remission is defined as a Montomery and Åsberg Depression Rating Scale (MADRS) total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomized treatment. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Full Remission During the Randomised Treatment Period | 110 | 95 |
Full functional remission is defined as a Sheehan Disability Scale (SDS) total score \<=6 and all SDS domain scores \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Full Functional Remission During the Randomised Treatment Period | 73 | 68 |
Full global score remission is defined as a Clinical Global Impression - Severity of Illness (CGI-S) score \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis, on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Full Global Score Remission During the Randomised Treatment Period | 143 | 121 |
The total time the patient spends in remission during randomised treatment. Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score. Time in remission is defined as the sum of days over all periods between Period B visits where remission was obtained. The period between two visits is counted as in remission if the patient was in remission when the period started.
| Number of days | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Total Time in Remission During the Randomised Treatment Period | 33.5 ± 46.1 | 30.0 ± 44.3 |
The time from randomisation until full remission has been obtained. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment. The time to full remission was calculated using Kaplan-Meier Methods.
| Days | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Time to Full Remission During the Randomised Treatment Period | NA (NA to NA) | NA (NA to NA) |
Full remission sustained is defined as having obtained full remission and remain in remission until completion of the study. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Full Remission Sustained During the Randomised Treatment Period | 105 | 84 |
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period | -5.9 ± 0.4 | -6.3 ± 0.4 |
The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.
| Units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period | -12.6 ± 0.6 | -11.5 ± 0.6 |
Response is defined as a \>=50% decrease from randomisation in MADRS total score.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Response at Week 6 During the Randomised Treatment Period | 76 | 82 |
Response is defined as a \>=50% decrease from randomisation in MADRS total score.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Response at Week 24 During the Randomised Treatment Period | 236 | 223 |
Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Remission at Week 6 During the Randomised Treatment Period | 46 | 53 |
Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.
| participants | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Remission at Week 24 in the Randomised Treatment Period | 198 | 176 |
The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period | -3.0 ± 0.3 | -2.9 ± 0.3 |
The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period | -6.7 ± 0.5 | -5.5 ± 0.5 |
The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period | -0.8 ± 0.1 | -0.8 ± 0.1 |
The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period | -1.7 ± 0.1 | -1.5 ± 0.1 |
The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period | 3.5 ± 0.4 | 3.2 ± 0.4 |
The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.
| units on a scale | Period B Placebo and ADT (24 Weeks Randomised Treatment) | Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) |
|---|---|---|
| Change From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period | 7.7 ± 0.7 | 6.2 ± 0.7 |
Collected over Randomisation to end of study (28 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo and ADT | — | 13/441 (2.9%) | 97/441 (22%) |
| Brexpiprazole and ADT | — | 9/444 (2%) | 108/444 (24.3%) |
| Event | Placebo and ADT | Brexpiprazole and ADT |
|---|---|---|
| Suicidal ideationPsychiatric disorders | 3/441 | 2/444 |
| Intentional overdoseInjury, poisoning and procedural complications | 2/441 | 0/444 |
| Ovarian cystReproductive system and breast disorders | 1/302 | 0/307 |
| InfluenzaInfections and infestations | 1/441 | 0/444 |
| Forearm fractureInjury, poisoning and procedural complications | 1/441 | 0/444 |
| False positive investigation resultInvestigations | 1/441 | 0/444 |
| Ruptured cerebral aneurysmNervous system disorders | 1/441 | 0/444 |
| SciaticaNervous system disorders | 1/441 | 0/444 |
| Major depressionPsychiatric disorders | 1/441 | 1/444 |
| Self injurious behaviourPsychiatric disorders | 1/441 | 0/444 |
| Event | Placebo and ADT | Brexpiprazole and ADT |
|---|---|---|
| Weight increasedInvestigations | 22/441 | 42/444 |
| NasopharyngitisInfections and infestations | 34/441 | 28/444 |
| HeadacheNervous system disorders | 31/441 | 34/444 |
| Accidental overdoseInjury, poisoning and procedural complications | 25/441 | 27/444 |
| Age, Continuous(years) | All Enrolled Patients |
|---|---|
| Mean | 47.3 ± 12.0 |
| Sex: Female, Male(Participants) | All Enrolled Patients |
|---|---|
| Female | 1402 |
| Male | 584 |
| Race (NIH/OMB)(Participants) | All Enrolled Patients |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 19 |
| White | 1918 |
| More than one race | 0 |
| Unknown or Not Reported | 46 |
| Region of Enrollment(participants) | All Enrolled Patients |
|---|---|
| Russian Federation | 121 |
| Romania | 15 |
| United States | 78 |
| Ukraine | 189 |
| United Kingdom | 168 |
| Canada | 30 |
| Latvia | 84 |
| Sweden | 85 |
| Finland | 136 |
| Poland | 325 |
| Mexico | 72 |
| Bulgaria | 119 |
| Lithuania | 76 |
| Germany | 325 |
| Estonia | 161 |
| Korea, Republic of | 2 |
Showing the first 100 of 107 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Jun 2013, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole